These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 35923275)

  • 1. National medicines policy development, Saudi Arabia.
    Almoteiry K; Alharf A; Al Hammad B; Aljuffali I; Al-Azemi N; Al-Ghaith T; Alhomidi S; Alshehri A; Seiter A; Herbst C; Pisani E
    Bull World Health Organ; 2022 Aug; 100(8):511-519. PubMed ID: 35923275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new approach to gathering pharmaceutical market data to support policy implementation and access to medicines: as demonstrated by malaria medicines in Zambia.
    Coghlan R; Stephens P; Mwale B; Siyanga M
    Malar J; 2018 Nov; 17(1):444. PubMed ID: 30497504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The right to health as the basis for universal health coverage: A cross-national analysis of national medicines policies of 71 countries.
    Perehudoff SK; Alexandrov NV; Hogerzeil HV
    PLoS One; 2019; 14(6):e0215577. PubMed ID: 31251737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implications of national tax policy on local pharmaceutical production in a southwestern state nigeria - qualitative research for the intersection of national pharmaceutical policy on health systems development.
    Obembe TA; Adenipekun AB; Morakinyo OM; Odebunmi KO
    BMC Health Serv Res; 2022 Feb; 22(1):264. PubMed ID: 35220971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmaceutical Pricing Policies and Procedures in Saudi Arabia: A Narrative Review.
    Khan TM; Emeka P; Suleiman AK; Alnutafy FS; Aljadhey H
    Ther Innov Regul Sci; 2016 Mar; 50(2):236-240. PubMed ID: 30227009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An analysis of China's national essential medicines policy.
    Guan X; Liang H; Xue Y; Shi L
    J Public Health Policy; 2011 Aug; 32(3):305-19. PubMed ID: 21614030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient access to medicines in two countries with similar health systems and differing medicines policies: Implications from a comprehensive literature review.
    Babar ZU; Gammie T; Seyfoddin A; Hasan SS; Curley LE
    Res Social Adm Pharm; 2019 Mar; 15(3):231-243. PubMed ID: 29678413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug policy: making effective drugs available without bankrupting the healthcare system.
    Laupacis A; Anderson G; O'Brien B
    Healthc Pap; 2002; 3(1):12-30. PubMed ID: 12811107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Administrative cases: an effective alternative to lawsuits in assuring access to medicines?
    Chagas VO; Provin MP; Amaral RG
    BMC Public Health; 2019 Feb; 19(1):212. PubMed ID: 30786892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rational use of medicines - Indian perspective!
    Mohanta GP; Manna PK
    Int J Risk Saf Med; 2015; 27 Suppl 1():S47-8. PubMed ID: 26639706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do national medicinal drug policies and essential drug programs improve drug use?: a review of experiences in developing countries.
    Ratanawijitrasin S; Soumerai SB; Weerasuriya K
    Soc Sci Med; 2001 Oct; 53(7):831-44. PubMed ID: 11522132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ensuring patient access to essential medicines while minimizing harmful use: a revised World Health Organization tool to improve national drug control policy.
    Gilson AM; Maurer MA; Ryan KM; Skemp-Brown M; Husain A; Cleary JF
    J Pain Palliat Care Pharmacother; 2011; 25(3):246-51. PubMed ID: 21882978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How to assure access of essential RMNCH medicines by looking at policy and systems factors: an analysis of countdown to 2015 countries.
    Briggs J; Embrey M; Maliqi B; Hedman L; Requejo J
    BMC Health Serv Res; 2018 Dec; 18(1):952. PubMed ID: 30526593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of prices paid by low-income countries - how price sensitive is government demand for medicines?
    Srivastava D; McGuire A
    BMC Public Health; 2014 Jul; 14():767. PubMed ID: 25073407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Providing affordable essential medicines to African households: the missing policies and institutions for price containment.
    Tetteh Ek
    Soc Sci Med; 2008 Feb; 66(3):569-81. PubMed ID: 18023953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Powers, engagements and resultant influences over the design and implementation of medicine pricing policies in Ghana.
    Koduah A; Baatiema L; Kretchy IA; Agyepong IA; Danso-Appiah A; de Chavez AC; Ensor T; Mirzoev T
    BMJ Glob Health; 2022 May; 7(5):. PubMed ID: 35589156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating community pharmacists' perspectives and practices concerning generic medicines substitution in Saudi Arabia: A cross-sectional study.
    Alkhuzaee FS; Almalki HM; Attar AY; Althubiani SI; Almuallim WA; Cheema E; Hadi MA
    Health Policy; 2016 Dec; 120(12):1412-1419. PubMed ID: 28228231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of pricing policy on the prices and supply of low-cost medicines in Shandong, China: evidence from an interrupted time series analysis.
    Rong X; Yin J; Duan S; Sun Q; Babar ZU
    BMC Public Health; 2020 Apr; 20(1):588. PubMed ID: 32349722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges to pharmaceutical policymaking: lessons from Australia's national medicines policy.
    Lipworth W; Doran E; Kerridge I; Day R
    Aust Health Rev; 2014 May; 38(2):160-8. PubMed ID: 24589424
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.